Group 1 - The core viewpoint of the article highlights the significant stock price increase of Insilico Medicine (3696.HK), which surged by 17% to reach a new high of 55 HKD, marking a cumulative increase of over 52% since its listing, with a market capitalization exceeding 30 billion HKD [1] - Insilico Medicine recently announced a research collaboration with Sivea, valued at 888 million USD, focusing on challenging targets in the oncology field to identify and develop new therapeutic drugs [1] - The stock price increase is attributed to multiple factors, including recent advancements in the AI healthcare industry, with Insilico's collaboration with Sivea and other strategic partnerships, such as the one with JinkoSolar's subsidiary by another AI pharmaceutical company, highlighting a trend of innovation in the sector [1]
港股异动丨英矽智能盘中大涨17%，股价创上市新高，市值超300亿港元